Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 14/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 14/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | F12 | P00748 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26645630 | 1.00 | CSNK1E (0.43) | CSNK1ECSNK1DGPR119F12MAPK11 | |
| SCHEMBL26645443 | 0.90 | CSNK1E (0.43) | CSNK1ECSNK1DMAPK11MAPK14 | |
| SCHEMBL30622922 | 0.90 | CSNK1E (0.43) | CSNK1ECSNK1DMAPK11MAPK14 | |
| SCHEMBL30622943 | 0.90 | CSNK1E (0.53) | CSNK1ECSNK1D | |
| SCHEMBL26645035 | 0.90 | CSNK1E (0.53) | CSNK1ECSNK1D | |
| SCHEMBL26645250 | 0.89 | CSNK1D (0.48) | CSNK1ECSNK1DGPR119 | |
| SCHEMBL26645466 | 0.89 | CSNK1D (0.49) | CSNK1ECSNK1DGPR119 | |
| SCHEMBL30622835 | 0.89 | CSNK1E (0.44) | CSNK1ECSNK1DMAPK14 | |
| SCHEMBL26645379 | 0.89 | CSNK1E (0.44) | CSNK1ECSNK1DMAPK14 | |
| SCHEMBL30622855 | 0.88 | CSNK1E (0.42) | CSNK1ECSNK1DGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | disclosed |